TMT PRO 18 plex19 May 2021 23:36
Issuance of key TMT® Patent and Introduction of 18plex TMTpro™ Services
Proteome Sciences is pleased to announce the issuance to it of U.S. Patent No. 10,976,321 relating to methods of analysis using isobaric mass tags. This patent, which covers the TMTcalibrator™ workflow, enables enhanced fluid biomarker discovery and single-cell proteomics and forms part of the intellectual property exclusively licensed to Thermo Fisher Scientific by the Company. Commercial users interested in performing any of the methods covered by U.S. Patent No. 10,976,321 or its foreign counterparts should contact the Thermo Fisher Scientific Licensing Team.
The Company is also launching new higher-throughput services using a recently developed, extended range of TMTpro™ reagents that now provide 18 channels, increasing throughput and enabling quantification of 100 samples in only 6 experiments.
Commenting, Dr. Ian Pike, Chief Scientific Officer, said: "These are key developments for the Company as we see increasing demand for our services across the drug-development and academic sectors. U.S. 10,976,321 is a key patent covering our TMTcalibrator™ technology, which is at the heart of our precision medicine efforts. We are updating the technology access program with our exclusive licensee Thermo Fisher Scientific, offering commercial users and providers of contract research services (CROs) an efficient way to obtain licenses to the TMT® patent portfolio where required.
Combined with the extension of TMTpro™ to 18plex, this represents the most powerful proteomics platform to identify and develop biomarkers that are essential to developing personalised medicine through more efficient, large-scale blood biomarker proteomics, as well as enabling the emerging field of single-cell proteomics".
Sign In
Follow the stocks
